facebook button Spectum: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Spectum: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer

Sponsor: Spectrum Pharmaceuticals, Inc.

A phase 2 trial of Tyrosine Kinase inhibitor Poziotinib for patients with metastatic Non-small Cell Lung cancer containing EGFR or HER2 exon 20 mutation that have undergone at least one prior line of therapy for metastatic disease.

For more information please contact the clinical research department: 631-675-5075